|
Patent Classification
Treatment,
Genetic/Inherited Related Disorders
-
Diagnosis and
treatment of diseases arising from defects in the tuberous sclerosis
pathway
-
Methods for detection of genetic disorders
-
Gene repair involving in vivo excision of targeting DNA
-
Method for producing proteins suitable for treating lysosomal storage
disorders
-
Diagnosis and treatment of diseases arising from defects in the tuberous
sclerosis pathway
-
Genetic suppression and replacement
-
DNA encoding a DNA repair protein
-
Treatment of glycogen storage disease type II
Treatment,
Gigantism/Acromegaly
-
DNA encoding growth hormone antagonists
-
Mutant
human growth hormones and their uses
Treatment, Glaucoma/Ocular
Hypertension
-
Memantine
titration/compliance dosage methods
-
Mouse with deficiency
of glutamate transporter GLAST function
-
Inhibitors of
glycogen synthase kinase-3 (GSK-3) for treating glaucoma
-
Methods of treating
neovascular glaucoma, macular degeneration and capillary proliferation
with alphavbeta3-specific antibodies
-
Use of serum amyloid
a gene in diagnosis and treatment of glaucoma and identification of
anti-glaucoma agents
-
Methods for diagnosing glaucoma and discovering anti-glaucoma drugs
-
Method for treating glaucoma
-
Use of AP-1 activators to treat glaucoma and ocular hypertension
-
Method for treating elevated intraocular pressure, including glaucoma
-
Use of recombinant gene delivery vectors for treating or preventing
diseases of the eye
-
Methods and compounds for prevention and
treatment of elevated intraocular pressure and related conditions
-
Treatment of ocular hypertension and glaucoma
-
Methods for treating glaucoma
-
Glaucoma treatment
-
Method of regulating pressure with an intraocular implant
-
Use of PARP inhibitors in the treatment of
glaucoma
-
Drug
delivery system for antiglaucomatous medication
-
Drug
of improving optic nerve head circulation disorder
-
Upregulation
of endogenous prostaglandins to lower intraocular pressure
-
Composition
and method for treating glaucoma
-
Inhibition of noninactivating Na channels of mammalian
optic nerve as a means of preventing optic nerve degeneration associated
with glaucoma
Treatment, Glycolipid
Storage Diseases/Gaucher's Disease
-
Combination drug therapy for glycolipid storage
diseases
Treatment, Gonorrhoea
-
Method of inhibiting formation of Neisseria gonorrhea and
Neisseria meningiditis
-
Screening of neisserial vaccine candidates and
vaccines against pathogenic neisseria
Treatment, Gout
-
Diagnosing an animal for pyrophosphate gout, osteoporosis, or
osteoarthritis by assaying intracellular pyrophosphate content in
peripheral blood cells
Treatment, Graft,
Bone/Tissue/Skin
-
Methods for enhancing
graft survival by modulating heme oxygenase activity
-
Matrix protein
compositions for grafting
-
Method and composition for skin grafts
-
Targeting pharmaceutical agents to injured tissues
-
Epidermal melanocyte culture formulations
-
Calcium phosphate bone graft material, process
for making same and osteoimplant fabricated from same
-
Biomaterial
derived from vertebrate liver tissue
Treatment, Growth Hormone
Related Disorders
-
Cysteine variants of erythropoietin
-
Site-specific preparation of polyethylene
glycol-GRF conjugates
-
Modified growth hormone
-
Prevention of
hyperinsulinemia in subjects undergoing growth hormone (GH) treatment
-
Non-aqueous injectable formulations for extended release
of somatotropin
-
Site-specific preparation of polyethylene glycol-grf
conjugates
Treatment, Gynecological
Related Disorders
-
Progesterone
receptor modulators with increased antigonadotropic activity for female
birth control and hormone replacement therapy
-
Method to produce a tampon that inhibits exoprotein production from gram
positive bacteria
-
Pharmaceutical preparation for the treatment of
gynecological diseases
-
Nasal spray steroid formulation and method
-
Methods and compositions for treating benign gynecological disorders
Treatment,
Haemophilus Influenzae Related Disorders
-
Immunogenic conjugates comprising a group B
meningococcal porin and an H. influenzae polysaccharide
-
Multi-component
vaccine comprising at least three antigens to protect against disease
cased by Haemophilus influenzae
-
Bioactive
rice flour extract useful for treatment of haemophilus influenzae
infections
-
OMP26
antigen from Haemophilus influenzae
Treatment, Hair
Growth/Alopecia/Hair Removal
-
Agent for slowing hair
loss and/or stimulating hair growth
-
Methods of culturing
dermal papilla cells
-
Method for promoting
hair growth
-
Compositions and methods
for dual therapies of hair graying and balding in follicular delivery
systems
-
Use of peptidic
conjugates for preparing compositions for alopecia preventive and curative
treatment
-
Herbal hair growth
inhibitor and depilation accelerator
-
Identification and use
of inhibitors of hair growth
-
Methods of promoting
hair growth
-
Compositions and
methods relating to prevention of chemotherapy-induced alopecia
-
Method for stimulating hair follicle cell
proliferation
-
Oligopeptides for promoting hair growth
-
Inhibitors of proteasomal activity for stimulating hair growth
-
Hair follicle growth factor proteins
-
Compositions and method for promoting the growth of human hair
-
Method of inhibiting hair growth
-
Inhibitors of proteasomal activity for stimulating hair growth
-
Methods of modulating hair growth
-
Methods of inducing hair growth and coloration
-
Treatment of alopecia
-
Method of treating hair loss
-
Methods for treating and preventing alopecia
-
Compositions containing minoxidil and saw
palmetto for treating baldness
-
Method to promote, stimulate and/or delay hair
loss by a brady kinin antagonist
-
Modulating body/cranial hair growth
-
Methods
for altering hair growth and hair pigmentation by apoptosis in the
follicular papillae and compositions therefor
-
Methods
for treating alopecia
-
Hair
growth stimulant
-
Topical
preparation for the treatment of hair loss
-
Composition
and method for topical treatment of androgenic alopecia
-
Preparation
for improving hair growth, the skin structure and/or nail regeneration
-
Minoxidil
compositions for external use
-
Sustained
release hair growth composition
-
Agents
and compositions thereof for the hair treatment
-
Dietary
supplement containing herbal extracts which promotes healthy hair
growth on the scalp
-
Pharmaceutical
composition comprising starch, a compound comprising boron, a compound
comprising zinc, and water, and a method of using same to encourage
hair growth
-
Hair
growers having actions of promoting proliferation of hair papilla
cells
Treatment, Hangover
-
Hangover relief composition
-
Hangover treatment
Treatment, Headache
-
Delivery of
compounds for the treatment of headache through an inhalation route
-
Composition of medicine for treating headache disease and process of
preparation and uses thereof
-
Methods for treating sinus headache
-
Methods for treating tension headache
-
Method for treating headache
-
Compositions and methods for relieving headache
symptoms in aspirin-sensitive headache sufferers
-
Cytotoxin (non-neurotoxin) for the treatment of human headache
disorders and inflammatory diseases
-
Method
and composition for treatment of headache using magnesium
Treatment,
Hearing Loss/Meniere Disease
-
Prevention of
cisplatin induced deafness
-
Composition and methods for the therapeutic use of an atonal-associated
sequence for deafness, osteoarthritis and abnormal cell proliferation
-
Transductin-1 and transductin-2 and applications to hereditary deafness
-
Compositions to detect
lesions associated with hearing loss in the cochlear gene, COCH5B2
-
Treatment of inner ear hair cells
-
Methods for treating hearing loss
-
Methods of diagnosis and treatment of meniere
disease
-
Treatment of inner ear hair cells
-
Cytokine antagonists for the treatment of sensorineural hearing loss
Treatment, Helicobacter
Infection
-
Glycoprotein having inhibitory activity against
helicobacter pylori colonization
-
Immunodulatory complex and use thereof in
helicobacter diseases
-
Treatment and prevention of helicobacter
infection
-
Adherence gene from Helicobacter pylori and
polypeptide coded thereby
-
Treatment and prevention of helicobacter
infection
Treatment,
Hematopoietic Cells, Restoring/Neutropenia
-
Methods for use of delivery composition for
expanding, activating, committing or mobilizing one or more pluripotent,
self-renewing and committed stem cells
-
Co-administration
of interleukin-3 mutant polypeptides with CSF'S for multi-lineage
hematopoietic cell production
Treatment,
Hemorrhoid/Anorectal Related Disorders
-
Anti-hemorrhoid composition and process for its manufacture
-
Hemorrhoid therapeutic treatment
-
Composition and method for the treatment of
anorectal disorders
-
Composition
of matter and method for the relief of hemorrhoidal conditions
-
Integrated
comprehensive hemorrhoid treatment compositions and regimen
Treatment,
Hepatic/Liver, Disorders/Hepatitis
-
Compositions and
methods for detection of hepatitis A virus nucleic acid
-
Biomarkers of liver
injury
-
Mutations in OAS1
genes
-
Nucleic acid and gene
derived from novel HCV strain and replicon-replicating cell using said
gene
-
Methods of treating
non-alcoholic steatohepatitis (NASH) using cysteamine products
-
Use of modified
cyclosporins for the treatment of HCV disorders
-
Treating hepatoma by
inhibiting expression of gankyrin
-
Liver stem cell
-
Methods of treating
travelers diarrhea and hepatic encephalopathy
-
Nucleotide vector
vaccine for immunization against hepatitis
-
Antibodies that
bind hepatocyte growth factor activator
-
Genetic
polymorphisms associated with liver fibrosis
-
Hepatitis-C virus type
4, 5 and 6
-
Structure-based
hepatitis C virus drug design
-
Treating hepatitis C
virus infection
-
Evolved interferon-alpha
polypeptides
-
Inducing cellular
immune responses to hepatitis B virus using peptide compositions
-
Hepatitis C virus
vaccine
-
L-ergothioneine, milk
thistle, and S-adenosylmethionine for the prevention, treatment and repair
of liver damage
-
Hepatitis B virus
surface antigen mutant and methods of detection thereof
-
Nucleic acid injected
into hepatic vein lumen
-
Compositions and
methods for detection of hepatitis A virus nucleic acid
-
Systems for expressing
toxic proteins, vectors and method of producing toxic proteins
-
Mammalian immortalized liver cell
-
Compositions and
methods for generation of infectious hepatitis C virus in immortalized human
hepatocytes
-
Method of treatment
of viral hepatitis C with interferon alpha 5
-
Chimeric GB virus B (GBV-B)
-
Methods of reducing
serum alanine transferase levels in a subject with hepatitis
-
Uses of DC-SIGN and
DC-SIGNR for inhibiting hepatitis C virus infection
-
Yeast-based
therapeutic for chronic hepatitis C infection
-
Hepatitis C virus
non-structural NS3/4A fusion gene
-
Replication of hepatitis C virus in non-hepatic epithelial and mouse
hepatic cells
-
Multivalent
vaccine composition having increased stability of capsular polysaccharide
-
Detection and treatment
of cancers of the liver
-
Hepatitis C Virus NS5B
polymerase inhibitor binding pocket
-
Diagnosis and treatment of hepatic disorders
-
Stabilized HBc chimer particles as
immunogens for chronic hepatitis
-
Treatment of hepatitis C
in the Asian population with subcutaneous interferon-beta
-
Therapeutic targets for treatment of HCV
infections, methods of treating HCV infections and compounds useful
therefor
-
Method for treating a viral infection
related or a chemical toxin related hepatic injury with deltorphin D
-
Drugs for liver diseases
-
Agents for treatment of HCV and methods of
use
-
Polynucleotides encoding a multiple epitope
fusion antigen for use in an HCV antigen/antibody combination assay
-
Constructs and methods for expression of
recombinant HCV envelope proteins
-
Regulatory elements for delivery to the
liver
-
GB virus C and methods of treating viral infections
-
Hepatocytes for therapy and drug screening made from embryonic stem cells
-
Complex of hepatitis B virus-specific antigenic peptides associated with
heat shock proteins and the application thereof
-
Human monoclonal antibody against hepatitis C virus E2 glycoprotein
-
Methods for the
treatment of hepatic disorders
-
Hepatitis C virus non-structural NS3/4A fusion gene
-
Method for therapy of liver tumors
-
Alanine- and glycine-containing therapeutic agent for hepatitis
-
Treatment of hepatitis C
with thymosin and peptide combination therapy
-
Hepatitis B virus surface antigen mutant and methods of detection
thereof
-
In vivo induction for
enhanced function of isolated hepatocytes
-
Nucleic acid injected
into hapatic vein lumen and delivered to primate liver
-
Hepatitis B virus
surface antigen mutant and methods of detection thereof
-
Methods for treating
viral infection using IL-28 and IL-29
-
Hepatic disorder
suppressant
-
Liver tumor marker
sequences
-
Humanized antibody specific for surface antigen pre-S1 of HBV and
preparation method thereof
-
Variable region of the monoclonal antibody against the HBV S-surface
antigen and a gene encoding the same
-
Remedies for hepatitis C
-
Method and compositions for treating hepatocellular cancer
-
HCV core protein binding agents for treatment of hepatitis C virus
infection
-
Cloned genome of infectious hepatitis C virus of genotype 2A and
uses thereof
-
Hepatic disorder suppressant
-
Genetic immunization with nonstructural proteins of hepatitis C
virus
-
Treatment of hepatic fibrosis with imatinib mesylate
-
Vaccine-induced
hepatitis B viral strain and uses thereof
-
Purified hepatitis C
virus envelope proteins for diagnostic and therapeutic use
-
Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
-
Avian hepatitis E virus, vaccines and methods of protecting against avian
hepatitis-splenomegaly syndrome and mammalian hepatitis
-
Hepatocurative effect of emblica officinalis against CYP 450
bio-activation hepatotoxicity of drugs
-
Utilization of
interferon alpha 5 in the treatment of viral hepatopathies
-
Propagation of human hepatocytes in non-human animals
-
Hepatitis A vaccines
-
Antigenic structural peptide, antigenic and
immunogenic compounds, and uses for detecting, preventing and treating an
HCV infection
-
Mosaic protein and restriction endonuclease assisted ligation method for
making the same
-
Self-replicating RNA molecule from hepatitis C
virus
-
Anti hepatitis C virus antibody and uses thereof
-
Synergistic composition of
trans-tetracos-15-enoic acid and Apocynin and method of treatment for
hepatotoxicity
-
3′terminal sequence of hepatitis C virus genome and diagnostic and
therapeutic uses thereof
-
Major neutralization site of hepatitis E virus and use of this
neutralization site in methods of vaccination and in methods of screening
for neutralizing antibodies to hepatitis E virus
-
Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C
virus and their use in the diagnosis, treatment, and prevention of
hepatitis C
-
Hepatitis B virus treatment
-
Methods and compositions for treating hepatitis B
-
Combined hepatitis B treatment
-
Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
-
Induction of viral mutation by incorporation of miscoding ribonucleoside
analogs into viral RNA
-
Freeze-dried hepatitis A attenuated live vaccine and its stabilizer
-
Hepatitis-C virus type 4, 5, and 6
-
Liver stem cell
-
Amino acid-containing albumin preparation
-
Vaccines containing ribavirin and methods of use
thereof
-
Methods for the simultaneous detection of HCV
antigens and HCV antibodies
-
Monoclonal antibodies to the human LDL receptor,
their production and use
-
Method of treating anemia caused by ribavirin treatment of hepatitis C
using erythropoietin alpha
-
Production of replicative hepatitis C virus
-
Ribavirin-pegylated interferon alfa induction HCV
combination therapy
-
Method of production of purified hepatitis a
virus particles and vaccine preparation
-
Reporter gene system for use in cell-based
assessment of inhibitors of the hepatitis C virus protease
-
Human monoclonal antibodies specific for
hepatitis C virus (HCV) E2 antigen
-
Long-term three dimensional tissue culture system
-
Treatment of liver disease and injury with CXC
chemokines
-
Self-replicating RNA molecule from hepatitis C
virus
-
In vivo induction for enhanced function of
isolated hepatocytes
-
Treatment of hepatitis C virus infections with
interleukin-10
-
Hepatitus A virus vaccines
-
Carrier for gene detection and its use for
detecting validity of interferon therapy
-
Mice comprising engrafted functional human
hepatocytes
-
Synthetic hepatitis C genes
-
Composition and method for diagnosing auto-immune hepatitis
-
Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
-
Peptides for inducing cytotoxic T lymphocyte
responses to hepatitus B virus
-
Antioxidant compositions and use for treatment of
hepatic steatosis and steatohepatitis
-
Pharmaceutical formulation useful for the treatment of hepatitis B,
hepatitis C and other viral infections of the liver and a process for its
preparation
-
Non-A, non-B, non-C, non-D, non-E hepatitis
reagents and methods for their use
-
Composition for the treatment of hepatitis including HCV
-
Complex of lipo-viro-particles, method of preparation and applications
-
Hepatitis B virus inhibitors
-
Vaccine composition for preventing or treating hepatitis C
-
Polyethylene glycol modified interferon therapy
-
Methods for the preparation of hepatitis C virus
multiple copy epitope fusion antigens
-
Antisense ogligonucleotides against Hepatitis B
viral replication
-
Combination therapy method for treating chronic
hepatitis B
-
Hepatitis B vaccine
-
Method for inducing hepatic fibrosis by repeated
administration of allylalcohol
-
Combination therapy for eradicating detectable
HCV-RNA in antiviral treatment naive patients having chronic hepatitis C
infection
-
Liver fat accumulation inhibitory composition, food additive for liver
fat accumulation, inhibition, and method of inhibiting liver fat
accumulation
-
Continuous low-dose cytokine infusion therapy
-
Combined hepatitis and herpesvirus antigen compositions
-
Production of replicative hepatitis C virus
-
Method for producing non-infectious recombinant picornavirus particles
-
Hepatitis A virus vaccines
-
Synthesis
and purification of hepatitis C virus-like particles
-
Liposomes
comprising peptide antigens derived from X protein of hepatitis B
virus
-
Hepatitis
C E1 and E2 truncated polypeptides and methods of obtaining the same
-
Polypeptides
displaying HBV antigenicity or hbv antigen specificity
-
Liver
cell clones for use in extracorporeal liver-assist device
-
Compositions
and methods for treating hepatitis-C
-
Hepatitis
C virus asialoglycoproteins
-
Combinations
and methods for promoting in vivo liver cell proliferation and
enhancing in vivo liver-directed gene transduction
-
Method of treating depressed reticuloendothelial
system function
-
L-ergothioneine, Milk thistle, and S-adenosylmethionine
for the prevention, treatment and repair of liver damage
Treatment,
Herpes/Epstein-Barr Related Illnesses
-
Compositions and methods for the therapy and diagnosis of
cytomegalovirus
-
Method of treating
genital herpes
-
Protective antigen of
epstein barr virus
-
Synthetic peptide,
inhibitor to DNA viruses
-
Unit dosage forms for the treatment of
herpes simplex
-
Detection of herpes
simplex virus types 1 and 2 by nucleic acid amplification
-
Diagnostics and therapy of epstein-barr virus in autoimmune disorders
-
Topical formulation
having effects on alleviating pain/inflammation caused by herpes virus
infection
-
Ligand for herpes
simplex virus entry mediator and methods of use
-
Aluminum-zirconium compound-based treatment for herpes simplex virus
lesions
-
Tape material for transcutaneous absorption
-
Immunization against herpes simplex virus
-
Topical transdermal treatments
-
Herpes virus complementing cell line
-
Method and composition for treating viral
outbreaks
-
Anti-HSV agent for inhibiting replication of
HSV-1 and HSV-2 and method of producing a substance having anti-HSV
activity
-
Peptides for inhibition of herpes simplex virus entry
-
Methods of treating human females susceptible to
HSV infection
-
Compositions and methods for the treatment of
viral disorders
-
Spliced gene of KSHV / HHV8, its promoter and
monoclonal antibodies specific for LANA2
-
Cellular proteins which mediate herpesvirus entry
-
Herpes simplex virus VP22 vaccines and methods of
use
-
Soluble herpesvirus glycoprotein complex vaccine
-
Bupropion to treat herpes viral diseases
-
Anti viral composition
-
Method for diagnosis of Epstein-Barr virus
associated disease
-
Sun-protection formulations active against herpes
simplex viruses
-
Unit dosage forms for the treatment of herpes
simplex
-
Combined hepatitis and herpesvirus antigen compositions
-
Human cytomegalovirus DNA constructs and uses
therefor
-
Method
for treating nerve injury pain associated with shingles
-
Herpes
simplex virus ORF P is a repressor of viral protein synthesis
-
Peptides
and nucleic acid sequences related to the Epstein Barr virus
-
Antimicrobial
treatment for herpes simplex virus and other infectious diseases
-
Method
and topical treatment composition for herpesvirus hominis
-
Anti-herpesviral
agent
-
Oligonucleotide
therapies for modulating the effects of herpesviruses
-
Treatment
of herpes infection with composition containing quaternary ammonium
compound and an anti-viral agent
-
Unit
dosage forms for the treatment of herpes simplex
Treatment, Homeostasis
-
Composition comprising theanine
Treatment,
Hormonal Replacement/Related Disorders
-
Subcutaneous
implants containing a degradation-resistant polylactide polymer
-
System for use by
compounding pharmacists to produce hormone replacement medicine customized for
each consumer
-
Oral pharmaceutical
products containing 17.beta.-estradiol-3-lower alkanoate, method of
administering the same and process of preparation
-
Methods and
materials for the treatment of testosterone deficiency in men
-
Transdermal
pharmaceutical composition
-
Treatment of
conditions relating to hormone deficiencies by administration of
progestins
-
Estrogen receptor
genes
-
17.beta.-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment
of androgen dependent diseases
-
Melanin-concentrating hormone analogs
-
Pharmaceutical compositions for nasal delivery of oestradiol and
norethisterone
-
Topical oestroprogestational compositions
with a systemic effect
-
Testosterone derivative
-
Bioadhesive tablet containing testosterone/testosterone ester mixtures
and method for producing a predetermined testosterone time-release
profile with same
-
Bio-identical hormones and method of use
-
Nasal spray formulation and method
-
Method for modulating steroidogenic activity
-
Laminates containing an active substance
transdermal system
-
Dosage forms and methods for oral delivery of
progesterone
-
Hormonal composition consisting of an oestrogen
compound and of a progestational compound
-
Polymeric delivery formulations of leuprolide with improved efficacy
-
Low dose estrogen interrupted hormone replacement therapy
-
Topical testosterone formulations and associated
methods
-
Method for the treatment of symptoms related to
normal hormonal variations in women
-
Pharmaceutical preparation adhering to the skin,
in particular a transdermal therapeutic system for the release of
17-.beta.-estradiol to the human organism
-
Method for the treatment of symptoms related to
normal hormonal variations in women
-
Methods for treating or reducing prediposition to breast cancer,
pre-menstrual syndrome or symptoms associated with menopause by
administration of phyto-estrogen
-
Hormone
replacement therapy
-
Transdermal
application of naturally occurring steroid hormones
Treatment,
Huntington's Disease
-
Method for
treatment of Huntington's disease through intracranial delivery of sirna
-
G-rich
polynucleotides for the treatment of Huntington's Disease
-
Antibodies that bind
to an epitope on the Huntington's disease protein
-
Composition and method for the detection of diseases associated with
amyloid-like fibril or protein aggregate formation
-
Method and compositions for treating diseases
mediated by transglutaminase activity
-
Antibodies
specific for proteins having polyglutamine expansions
Treatment, Hurler Syndrome/Mucopolysaccharidosis
I
-
Methods for treating diseases caused by
deficiencies of recombinant alpha-L-iduronidase
Treatment,
Hyperbilirubinemia
-
Inhibition of neonatal hyperbilirubinemia in
breast fed infants
Treatment, Hyperlipidemia
-
Target for treating athersclerosis, obesity and
type II diabetes
-
Methods and compositions for the treatment of defects in lipoprotein
metabolism
-
Charged lipid compositions and methods for their
use
-
Intermediate release nicotinic acid compositions
for treating hyperlipidemia
-
Mutual prodrug of amlodipine and atorvastatin
-
Method for treating hypercholesterolemia,
hyperlipidemia, and atherosclerosis
-
Composition and method for treatment of
gastrointestinal disorders and hyperlipidemia
Treatment,
Hyperphosphatemia
-
Preventives and/or remedies for hyperphosphatemia
-
Crosslinked anion-exchange resin or salt thereof
and phosphorus adsorbent comprising the same
Treatment,
Hypertension Related Disorders
-
Method of
treating hypertension and reducing serum lipase activity
-
Use of compounds
that bind soluble endoglin and SFLT-1 for the treatment of pregnancy
related hypertensive disorders
-
Therapeutic combination
of a VEGF antagonist and anti-hypertensive agent
-
Method of
predicting genetic risk for hypertension
-
Ace inhibitory peptides
from plant materials
-
Method for
predicting pregnancy-induced hypertension
-
Hypotensors
-
Method for producing a chitosan containing
salt having a function of lowering blood pressure
-
Materials and methods for the treatment of hypertension and angina
-
Drug response marker in beta-1 adrenergic receptor gene
-
Scorpion peptide as hypotensive agent
-
Anti-hypertensive
dietary supplement
-
Angiopoietins and methods of treating hypertension
-
Felodipine transdermal device and methods
-
Stabilization of
quinapril using magnesium oxide
-
Agent for preventing, improving or treating hypertension
-
Process for producing a product containing antihypertensive tripeptides
-
Method for preparing nicotianamine or nicotianamine-containing product
-
Treatment of hypertension using growth hormone in
mammals subjected to fetal programming
-
Agents for improving lipid metabolism and reducing high blood pressure
-
Angiotensin converting enzyme homolog and uses therefor
-
Method of assaying modulators of hypertension
-
Transdermal administration of ACE inhibitors
-
Mutual prodrug of amlodipine and atorvastatin
-
Hypertension-treatment and cholesterol-depressant
composition comprising extract from mixture of Panax notoginseng and
Salvia miltiorrhiza and method of preparing the same
-
Detection of hypertension using immunoreactive
metabolic products
-
Methods of treating hypertension
-
Drug screening and diagnosis based on paracrine tubular
renin-angiotensin system
-
Monohydrate lisinopril
-
Preventive, alleviative or remedy for
hypertension
-
Amorphous compound
-
Satiety inducing composition comprising
Neuropeptide Y analogues and methods of inducing satiety and treating a
disease or condition associated with it
-
Sodium
ion absorption inhibitors, sodium ion excretion accelerators, and
preventive and therapeutic agents for diseases resulting from
excessive intake of common salt
-
Pharmaceutical
composition comprising at least one aminopeptidase A inhibitor
-
Transdermally
administrable medicament with ACE inhibitors
-
Functional
sodium chloride compositions
-
Transdermal
administration of fenoldopam
Treatment,
Hypo/Hyper-glycemia
-
Methods and kits
for preventing hypoglycemia
-
Methods relating
to hypoglycemic unawareness
-
Yeast cell walls for
the treatment or prevention of hyperglycemia or for the stabilization of
glycemia
-
Disaccharide derivatives for treating hyperglycaemia
-
Blood glucose modulating compositions and methods
-
Method for inhibiting increase of blood sugar
level or lowering blood sugar level with a lagerstroemia extract
-
Raising
blood sugar level in hypoglycemic mammals by administering inhibitors
of dipeptidyl peptidase IV
|
